Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed sentiment. While the company reports decreased R&D and SG&A expenses, an increase in interest expense and a significant net loss raise concerns. The Q&A highlights management's optimism about future trials, yet lacks specifics on enrollment and liquidity strategies. The positive outlook on new data readouts and potential market opportunities is tempered by financial challenges. These mixed signals suggest a neutral impact on stock price, with no strong catalysts for a significant move in either direction.
Key Financial Performance
Total revenue for Q2 2025 $37.9 million, a decrease from $42.8 million in Q2 2024. The decline was primarily due to $6 million of nonrecurring license-related revenue recognized in Q2 2024.
U.S. XPOVIO net product revenue for Q2 2025 $29.7 million, an increase from $28 million in Q2 2024. The increase was attributed to consistent demand and a reduction in gross-to-net provisions.
Gross-to-net provisions for XPOVIO in Q2 2025 26.8%, down from 45% in Q1 2025 and 29.3% in Q2 2024. The decline was driven by mix and lower 340B discounts.
R&D expenses for Q2 2025 $32.8 million, a 15% decrease from $38.4 million in Q2 2024. The reduction was due to lower headcount, contractor costs, and clinical trial expenses.
SG&A expenses for Q2 2025 $28.5 million, an 8% decrease from $31.1 million in Q2 2024. The decrease was due to cost reduction initiatives.
Interest expense for Q2 2025 $11.2 million, an increase from $8.9 million in Q2 2024. The increase was due to refinancing in Q2 2024, which raised interest expense.
Royalty revenue for Q2 2025 $1.6 million, a 28% increase from Q2 2024. The increase was due to higher global demand for XPOVIO and NEXPOVIO.
Net loss for Q2 2025 $37.3 million or $4.32 per share. This includes $11.2 million in interest expense and $2 million in noncash losses from remeasurement of derivatives and warrants.
Net loss from operations for Q2 2025 $24.5 million, reflecting the performance of the core business.
Cash, cash equivalents, restricted cash, and investments as of Q2 2025 $52 million, a decrease from $109.1 million as of December 31, 2024. The decrease was due to operational expenses and debt obligations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Phase III SENTRY trial: Enrollment for the Phase III SENTRY trial in JAK-naive myelofibrosis is expected to close this week. The trial aims to redefine the standard of care with selinexor plus ruxolitinib, targeting a $1 billion annual revenue potential in the U.S. alone.
Endometrial cancer trial: Enrollment in the export EC042 trial for p53 wild-type endometrial cancer is progressing steadily, with top-line data expected in mid-2026.
Multiple myeloma trial: The Phase III EMN29 SPd trial aims to demonstrate an all-oral triplet treatment option for multiple myeloma, with top-line data expected in the first half of 2026.
Global expansion: Selinexor is now approved in 50 countries, contributing to a 28% increase in royalty revenue to $1.6 million in Q2 2025.
Revenue performance: XPOVIO net product revenue was $29.7 million in Q2 2025, up 6% year-over-year. Full-year 2025 revenue guidance is $140-$155 million.
Cost optimization: R&D and SG&A expenses decreased by 15% and 8% respectively, due to workforce reductions and cost-saving initiatives.
Liquidity management: The company is addressing near-term debt maturity in October 2025 and exploring financing and strategic alternatives to enhance liquidity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Constraints and Debt Maturity: The company is operating under financial constraints with a near-term debt maturity in October 2025. This creates liquidity challenges and necessitates active engagement with lenders and advisers to enhance liquidity and maximize value.
Market Competition: The multiple myeloma market is highly competitive and becoming more so each year, which could impact the company's ability to maintain or grow its market share for XPOVIO.
Enrollment Challenges in Clinical Trials: Enrollment in the Phase II SENTRY 2 trial has been slower than anticipated, partly due to prioritization of the Phase III SENTRY trial and the limited patient population with specific eligibility criteria.
Regulatory and Clinical Trial Risks: The success of the company's strategic objectives heavily depends on the outcomes of ongoing Phase III clinical trials in myelofibrosis and endometrial cancer. Any unfavorable results could significantly impact the company's future prospects.
Revenue Decline and Financial Performance: Total revenue for Q2 2025 declined compared to Q2 2024, primarily due to nonrecurring license-related revenue in the prior year. This decline, coupled with increased interest expenses, highlights financial pressures.
Operational Cost Management: The company has implemented cost reduction initiatives, including a 20% workforce reduction, to manage expenses. However, these measures may impact operational efficiency and employee morale.
Supply Chain and Manufacturing Risks: The company faces potential risks related to the supply chain and manufacturing processes, which could affect the timely delivery of products and clinical trial materials.
Dependence on Key Products: The company's financial health is heavily reliant on the success of XPOVIO and its potential approval for new indications. Any setbacks in these areas could adversely affect revenue and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III SENTRY trial in myelofibrosis: The company expects to close new patient screening this week and anticipates top-line data in March 2026. The trial aims to redefine the standard of care for myelofibrosis patients with a potential peak revenue of $1 billion annually in the U.S. alone.
Phase III export EC042 trial in endometrial cancer: Top-line data is expected in mid-2026. The trial targets p53 wild-type and MMR-proficient tumors, representing approximately 50% of advanced or recurrent endometrial cancer cases.
Phase III EMN29 SPd trial in multiple myeloma: Top-line data is expected in the first half of 2026. The trial aims to demonstrate the potential of an all-oral triplet treatment option for multiple myeloma patients.
Revenue guidance for 2025: The company expects total revenue of $140 million to $155 million, with U.S. XPOVIO net product revenue projected at $110 million to $120 million.
Cost reduction initiatives: A 20% workforce reduction is expected to lower annual spending by approximately $13 million starting in 2026.
Liquidity and financing: The company is working with advisers to explore financing and strategic alternatives to address liquidity and maximize value, with current liquidity expected to fund operations into January 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the biggest worry about the potential readout for myelofibrosis?
A:Management expressed a high level of excitement rather than worry. They highlighted the compelling SVR data, symptom improvement, and disease modification data, including cytokines, bone marrow fibrosis, and hemoglobin stabilization. They are optimistic about the combination of selinexor and ruxolitinib improving key endpoints and patient outcomes.
Q:How is the company preparing for three big data readouts next year?
A:The company is leveraging its commercial, payer, and medical affairs capabilities to prepare for the data readouts in myelofibrosis, XPORT-MM-031 trial, and endometrial cancer. They are building on their foundation in multiple myeloma and are ready to bring these treatments to patients rapidly, pending positive data.
Q:What are the baseline characteristics for the pivotal MF combo study, and how might they impact results?
A:Higher baseline TSS is expected to lead to more meaningful outcomes, such as a 50% improvement in TSS or an average reduction in mean TSS at week 24. The company is encouraged by the evolution of baseline TSS in the Phase III trial.
Q:Why are lower rates of Grade 3/4 anemia observed with the combination therapy, and how important is this for physicians?
A:The lower rates of Grade 3/4 anemia are likely due to disease modification with selinexor and ruxolitinib, including decreases in key cytokines and improvements in bone marrow fibrosis. This is important for physicians as it translates to both efficacy and safety improvements, potentially increasing uptake of the combination therapy.
Q:What are the revenue drivers and inventory trends for the company?
A:Inventory was consistent across the period, and there was an improvement in GTN. Demand remained relatively consistent, balancing the revenue drivers.
Q:What is the enrollment progress for the endometrial Phase III study?
A:Enrollment is steady, with a focus on biomarker-driven maintenance. The company anticipates top-line results in mid-2026 but has not disclosed specific enrollment numbers.
Q:How will the protocol amendment for the SENTRY-2 study help with enrollment, and what is the bar for success?
A:The amendment will allow patients with baseline platelet counts of 50 and above to enroll, potentially increasing enrollment. The bar for success remains 25%-30% efficacy relative to historical controls of approximately 15%.
Q:What are the reasons for improved tolerability in the Phase III study compared to Phase I?
A:Improved tolerability, especially in GI toxicity, is attributed to the consistent use of dual antiemetics in Phase III, which was not the case in Phase I. This led to significant reductions in nausea and vomiting rates.
Q:What is the company's view on recent FDA leadership changes and their impact on regulatory alignment?
A:The company has not received additional feedback since the third quarter of 2024 and remains confident in the FDA's position on the Phase III endpoints. They view the FDA's focus on accelerating access to treatments positively.
Q:What scenarios are being explored to enhance liquidity and maximize value?
A:The company is exploring a full range of financing and strategic alternatives, including those related to XPOVIO. They have engaged Centerview Partners to assist but have not disclosed specific actions or developments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific enrollment numbers for the endometrial Phase III study and did not disclose detailed scenarios being explored to enhance liquidity and maximize value. Additionally, they did not provide a clear answer on the potential impact of FDA leadership changes on their regulatory strategy.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Corporate Communications
Dr
Grade
III SENTRY
III trial
Phase III
Relations Corporate
Research Division
SENTRY trial
Slide opportunity
TEAEs
anemia
baseline
bone marrow
burden
combination ruxolitinib
combination therapy
criterion
disease modification
event
fatigue
grade
hemoglobin
increase progenitor
inhibitor myelofibrosis
interest expense
liquidity
loss
mind
month follow
patient combination
patient myelofibrosis
safety patient
selinexor monotherapy
selinexor ruxolitinib
warrant
KPTI Transcript
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary provides a mixed outlook. The company shows positive financial performance with increased revenue and improved net loss figures. However, the critical dependency on the Phase III SENTRY trial results introduces significant risk, as negative outcomes could impact strategic objectives. Additionally, no shareholder return plans were discussed, and cash reserves have decreased. The Q&A section did not provide further insights to shift sentiment. Overall, the balance of positive financials and potential risks leads to a neutral sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call reflects strong financial guidance, a promising Phase III trial for myelofibrosis, and a strategic focus on growth and financial discipline. Q&A insights highlight positive analyst sentiment and manageable safety profiles. Despite some uncertainties in management responses, the optimistic outlook on selinexor's potential and strategic market positioning suggests a positive stock reaction. The absence of negative catalysts like guidance cuts or financial distress further supports a positive sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call presents a mixed outlook. While financial performance shows improvements in cost management and revenue growth, the company's guidance and liquidity concerns raise uncertainties. The Q&A section highlights potential growth in myelofibrosis treatment but lacks clarity on financing and market positioning. The absence of a strong catalyst like a new partnership or record revenue tempers expectations, resulting in a neutral sentiment.
Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reflects a mixed sentiment. While the company reports decreased R&D and SG&A expenses, an increase in interest expense and a significant net loss raise concerns. The Q&A highlights management's optimism about future trials, yet lacks specifics on enrollment and liquidity strategies. The positive outlook on new data readouts and potential market opportunities is tempered by financial challenges. These mixed signals suggest a neutral impact on stock price, with no strong catalysts for a significant move in either direction.
KPTI Slides
KPTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
